Related references
Note: Only part of the references are listed.Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials
J. A. Davidson et al.
DIABETIC MEDICINE (2020)
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
L. Meneghini et al.
DIABETIC MEDICINE (2020)
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Chiara Maria Assunta Cefalo et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study
Angelo Maria Patti et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
John J. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
Clara Garcia-Carro et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications
Ravi Kant et al.
WORLD JOURNAL OF DIABETES (2019)
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Manfredi Rizzo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes
Philip Home et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis
Shaylee C. Peterson et al.
CURRENT DIABETES REVIEWS (2018)
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
Julio Rosenstock et al.
DIABETES CARE (2018)
Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
Matthew J. O'Brien et al.
JAMA NETWORK OPEN (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Hertzel C. Gerstein et al.
DIABETES OBESITY & METABOLISM (2018)
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
Mirna S. Abd El Aziz et al.
DIABETES OBESITY & METABOLISM (2017)
Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels
Harold E. Bays et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
Seon-Ah Cha et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
Junfeng Li et al.
FRONTIERS IN PHYSIOLOGY (2017)
Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
Srikanth Yandrapalli et al.
JOURNAL OF THORACIC DISEASE (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kare I. Birkeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J. Jardine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Julie A. Lovshin
CANADIAN JOURNAL OF DIABETES (2017)
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
Ira Gantz et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Gian Paolo Fadini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus
Lawrence H. Young et al.
CIRCULATION (2017)
Evidence-based goals in LDL-C reduction
Handrean Soran et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal et al.
DIABETES OBESITY & METABOLISM (2017)
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
Toshiyuki Hayashi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
Keith C. Ferdinand et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Albiglutide: a unique GLP-1 receptor agonist
Marc S. Rendell
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Rhonda Bentley-Lewis et al.
AMERICAN HEART JOURNAL (2015)
Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
Keiichi Torimoto et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Feng Sun et al.
CLINICAL THERAPEUTICS (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
Ali A. Rizvi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Oxidized Low-Density Lipoprotein Contributes to Atherogenesis via Co-activation of Macrophages and Mast Cells
Chong Chen et al.
PLOS ONE (2015)
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
Robert R. Henry et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
Michaela Diamant et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J. V. McMurray et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials
Michael Grimm et al.
POSTGRADUATE MEDICINE (2013)
Effects of Dapagliflozin on Cardiovascular Risk Factors
Agata Ptaszynska et al.
POSTGRADUATE MEDICINE (2013)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
M. A. Bush et al.
DIABETES OBESITY & METABOLISM (2009)
Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting
Rajat Bhushan et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2009)
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Manfredi Rizzo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
Kaspar Berneis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Share Paper
